AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39067464 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation
Number of subjects: 48
Study 39067509 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine HCl 0.15% nasal spray (2 sprays per nostril)
Number of subjects: 110
Study 39067509 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 110
Study 39067513 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP POCT
Number of subjects: 404
Study 39067513 — intervention group
Group type: COMPARATOR
Intervention: Control (no CRP POCT)
Number of subjects: 404
Study 39067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical balloon (Foley)
Number of subjects: 32
Study 39067560 — intervention group
Group type: COMPARATOR
Intervention: Osmotic dilators (Dilapan-S)
Number of subjects: 32
Study 39067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 39067618 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors prescribed at discharge
Number of subjects: 2247
Study 39067619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (PVI)
Number of subjects: 196
Study 39067619 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber pacemaker implantation with subsequent AVN ablation (PACE)
Number of subjects: 196
Study 39067649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic partial coverage indirect adhesive restorations (PCIARs) luted with light-cured composite resin (Filtek Z250, 3 M ESPE)
Number of subjects: 60
Study 39067764 — intervention group
Group type: EXPERIMENTAL
Intervention: Photovoice intervention
Number of subjects: 67
Study 39067870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carvedilol and VBL (group C)
Number of subjects: 330
Study 39067870 — intervention group
Group type: COMPARATOR
Intervention: Group C (Combination)
Number of subjects: 330
Study 39067870 — intervention group
Group type: COMPARATOR
Intervention: Group A (Carvedilol)
Number of subjects: 330
Study 39067870 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 330
Study 39067873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg intravenously every 6 weeks plus nivolumab 240 mg intravenously every 2 weeks until disease progression or other criteria met.
Number of subjects: 21
Study 39067876 — intervention group
Group type: EXPERIMENTAL
Intervention: Join4Joy approach in physical activity programmes, consisting of twelve, 1-hour weekly sessions of structured, supervised, group-based physical activity.
Number of subjects: 144
Study 39067883 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance by two midwives
Number of subjects: 2221
Study 39067883 — intervention group
Group type: COMPARATOR
Intervention: Assistance by one midwife (standard care)
Number of subjects: 2221
Study 39067885 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection Tracking in Travellers (ITIT) app
Number of subjects: 609
Study 39068060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO15)
Number of subjects: 366
Study 39068060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO30)
Number of subjects: 366
Study 39068060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 366
Study 39068298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Coronary Syndrome (ACS)
Number of subjects: 308
Study 39068298 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-angiography group (ACS patients)
Number of subjects: 308
Study 39068298 — intervention group
Group type: COMPARATOR
Intervention: Stable Coronary Artery Disease (Control)
Number of subjects: 308
Study 39068385 — intervention group
Group type: EXPERIMENTAL
Intervention: Back to Living Well program (12-week physical activity, education, and self-management program)
Number of subjects: 90
Study 39068432 — intervention group
Group type: EXPERIMENTAL
Intervention: SurgeCon quality improvement program
Number of subjects: 372
Study 39068435 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week progressive home-based neurodynamic exercise intervention (n=26)
Number of subjects: 108
Study 39068435 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection (n=26)
Number of subjects: 108
Study 39068435 — intervention group
Group type: COMPARATOR
Intervention: Advice (n=26)
Number of subjects: 108
Study 39068435 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (neurodynamic exercise, steroid injection, advice)
Number of subjects: 108
Study 39068465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, family-based diet and physical activity counseling delivered by a multidisciplinary team (pediatrician, nurse, clinical nutritionist)
Number of subjects: 80
Study 39068465 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 80
Study 39068739 — intervention group
Group type: EXPERIMENTAL
Intervention: TPIV200 + GM-CSF
Number of subjects: 120
Study 39068739 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF alone
Number of subjects: 120
Study 39068745 — intervention group
Group type: EXPERIMENTAL
Intervention: MG-ADL score
Number of subjects: 0
Study 39068745 — intervention group
Group type: EXPERIMENTAL
Intervention: MG-ADL item level scores
Number of subjects: 0
Study 39068745 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA including MG-ADL, QMG, MG-QOL15r, EQ-5D-5L
Number of subjects: 0
Study 39068937 — intervention group
Group type: EXPERIMENTAL
Intervention: Active weekly fever screening plus monthly RDT testing and treatment (group 3)
Number of subjects: 906
Study 39068937 — intervention group
Group type: EXPERIMENTAL
Intervention: Active weekly fever screening (group 2)
Number of subjects: 906
Study 39068937 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 906
Study 39068937 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monthly RDT testing and treatment (group 3)
Number of subjects: 906
Study 39068945 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific therapy guided by a 90-gene expression assay
Number of subjects: 182
Study 39068945 — intervention group
Group type: COMPARATOR
Intervention: Empirical chemotherapy
Number of subjects: 182
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity limitations (self-reported difficulty with walking, grasping, bending, seeing close, seeing far, speaking, hearing)
Number of subjects: 175660
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing close limitation
Number of subjects: 175660
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing far limitation
Number of subjects: 175660
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasping limitation
Number of subjects: 175660
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bending limitation
Number of subjects: 175660
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking limitation
Number of subjects: 175660
Study 39068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of gait, visual, and hearing aids
Number of subjects: 175660
Study 39068985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach with text reminders
Number of subjects: 0
Study 39068985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed FIT-DNA with patient support
Number of subjects: 0
Study 39069087 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton or photon beam therapy
Number of subjects: 23
Study 39069087 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study 39069096 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of original wild-type BNT162b2
Number of subjects: 461
Study 39069096 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated (control group)
Number of subjects: 461
Study 39069154 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (two, 3-hour manualized online sessions spaced 1 week apart)
Number of subjects: 129
Study 39069154 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 129
Study 39069239 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 59
Study 39069239 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 59
Study 39069239 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 Gy
Number of subjects: 59
Study 39069239 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 Gy
Number of subjects: 59
Study 39069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate repletion
Number of subjects: 1000
Study 39069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily phosphate measurements
Number of subjects: 1000
Study 39069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for 28- and 90-day all-cause mortality
Number of subjects: 1000
Study 39069258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Dysfunction Score (GIDS)
Number of subjects: 1400
Study 39069269 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg C15:0 daily for 12 weeks
Number of subjects: 30
Study 39069269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 39069451 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARTER intervention (family members trained to support nursing staff to take and record vital signs every 4 hours after surgery)
Number of subjects: 1395
Study 39069451 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1395
Study 39069466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (DI) program for 12 weeks
Number of subjects: 45
Study 39069466 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight individuals (control group)
Number of subjects: 45
Study 39069466 — intervention group
Group type: EXPERIMENTAL
Intervention: Before DI
Number of subjects: 45
Study 39069466 — intervention group
Group type: EXPERIMENTAL
Intervention: Before and after DI
Number of subjects: 45
Study 39069466 — intervention group
Group type: EXPERIMENTAL
Intervention: After DI
Number of subjects: 45
Study 39069599 — intervention group
Group type: EXPERIMENTAL
Intervention: EX60min (exercise 60 minutes post meal)
Number of subjects: 40
Study 39069599 — intervention group
Group type: COMPARATOR
Intervention: EX120min (exercise 120 minutes post meal)
Number of subjects: 40
Study 39069599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rapid aspart (insulin type)
Number of subjects: 40
Study 39069599 — intervention group
Group type: COMPARATOR
Intervention: Aspart (insulin type)
Number of subjects: 40
Study 39069614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet over 8 weeks
Number of subjects: 2
Study 39069614 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet over 8 weeks
Number of subjects: 2
Study 39069629 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffness-customized PD-AFO
Number of subjects: 20
Study 39069629 — intervention group
Group type: COMPARATOR
Intervention: No AFO
Number of subjects: 20
Study 39069629 — intervention group
Group type: COMPARATOR
Intervention: SOC AFO
Number of subjects: 20
Study 39069644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (MBSR) applied for 8 weeks, followed by individual repetition for another 8 weeks
Number of subjects: 151
Study 39069644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 151
Study 39069898 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-T2D
Number of subjects: 20
Study 39069898 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-T2D plasma-derived small extracellular vesicles
Number of subjects: 20
Study 39069898 — intervention group
Group type: COMPARATOR
Intervention: Healthy peers
Number of subjects: 20
Study 39069917 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated chronic hypertension
Number of subjects: 877
Study 39069917 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated chronic hypertension
Number of subjects: 877
Study 39069917 — intervention group
Group type: EXPERIMENTAL
Intervention: No hypertension
Number of subjects: 877
Study 39069917 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP reduction
Number of subjects: 877
Study 39069967 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 180 mg
Number of subjects: 24
Study 39069967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 39070019 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min daily meditation practice
Number of subjects: 17
Study 39070019 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min daily meditation practice
Number of subjects: 17
Study 39070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals with HIV
Number of subjects: 209
Study 39070044 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-HIV individuals)
Number of subjects: 209
Study 39070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Former and current smoking
Number of subjects: 209
Study 39070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased predicted anti-spike immunoglobulin G titer
Number of subjects: 209
Study 39070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccinations
Number of subjects: 209
Study 39070173 — intervention group
Group type: EXPERIMENTAL
Intervention: ALARM model (deep learning radiomics with clinical variables)
Number of subjects: 1858
Study 39070173 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (n=221, 11.9%) and medium-risk group (n=433, 23.3%)
Number of subjects: 1858
Study 39070176 — intervention group
Group type: EXPERIMENTAL
Intervention: S-UAS
Number of subjects: 320
Study 39070176 — intervention group
Group type: COMPARATOR
Intervention: traditional UAS
Number of subjects: 320
Study 39070183 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 548
Study 39070183 — intervention group
Group type: COMPARATOR
Intervention: No RBC transfusion (Control)
Number of subjects: 548
Study 39070183 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ejection fraction
Number of subjects: 548
Study 39070183 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 548
Study 39070625 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based interventions (EBIs) including low literacy patient education, provider education, EMR tools, FIT kit distribution, and cancer control champion support.
Number of subjects: 0
Study 39070653 — intervention group
Group type: EXPERIMENTAL
Intervention: MABT plus MOUD
Number of subjects: 303
Study 39070653 — intervention group
Group type: COMPARATOR
Intervention: MOUD only
Number of subjects: 303
Study 39070744 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 201
Study 39070744 — intervention group
Group type: COMPARATOR
Intervention: Written material
Number of subjects: 201
Study 39070744 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (frequent use)
Number of subjects: 201
Study 39070742 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused lung, cardiac, and deep venous ultrasound
Number of subjects: 150
Study 39070742 — intervention group
Group type: COMPARATOR
Intervention: Direct diagnostic imaging (control)
Number of subjects: 150
Study 39070853 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg oral tablet
Number of subjects: 1162
Study 39070853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study 39070895 — intervention group
Group type: COMPARATOR
Intervention: ICOnnecta't program (control group) - a digital stepped intervention addressing psychosocial needs
Number of subjects: 88
Study 39070895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive module (Level 1: cognitive screening using FACT-Cog PCI; Level 2: cognitive psychoeducational campus; Level 3: online cognitive training through CogniFit software)
Number of subjects: 88
Study 39070895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive module integration
Number of subjects: 88
Study 39071916 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg L and 2 mg Z softgel (Carotenoid Group)
Number of subjects: 47
Study 39071916 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care prenatal vitamins with placebo softgel (Control Group)
Number of subjects: 47
Study 39072039 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of a polygenic risk score (PRS) for coronary heart disease (CHD)
Number of subjects: 203
Study 39072039 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy initiation and duration
Number of subjects: 203
Study 39072039 — intervention group
Group type: COMPARATOR
Intervention: Framingham risk score (FRS)
Number of subjects: 203
Study 39072042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin-piperaquine+single-low dose primaquine
Number of subjects: 6505
Study 39072042 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SMC) with sulfadoxine-pyrimethamine+amodiaquine
Number of subjects: 6505
Study 39072042 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA
Number of subjects: 6505
Study 39072042 — intervention group
Group type: COMPARATOR
Intervention: SMC
Number of subjects: 6505
Study 39072042 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA and SMC
Number of subjects: 6505
Study 39072044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group (PENG) block
Number of subjects: 101
Study 39072044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral quadratus lumborum block (QLB)
Number of subjects: 101
Study 39072044 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG
Number of subjects: 101
Study 39072044 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB
Number of subjects: 101
Study 39072232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-sparing resuscitation strategy
Number of subjects: 400
Study 39072232 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 39072240 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a nephroprotective care bundle as recommended by KDIGO guidelines.
Number of subjects: 618
Study 39072240 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control) group.
Number of subjects: 618
Study 39072257 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure
Number of subjects: 369
Study 39072257 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 369
Study 39072280 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking tobacco
Number of subjects: 261
Study 39072356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vepdegestrant (ARV-471)
Number of subjects: 0
Study 39072356 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant
Number of subjects: 0
Study 39072392 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39072466 — intervention group
Group type: EXPERIMENTAL
Intervention: Core foot system training
Number of subjects: 0
Study 39072466 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation methods
Number of subjects: 0
Study 39072654 — intervention group
Group type: EXPERIMENTAL
Intervention: Superset training
Number of subjects: 0
Study 39072654 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 0
Study 39072654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 39072750 — intervention group
Group type: COMPARATOR
Intervention: Tumor-infiltrating lymphocytes (TILs) in metastases
Number of subjects: 550
Study 39072750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined positive score (CPS)
Number of subjects: 550
Study 39072750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor proportion score (TPS)
Number of subjects: 550
Study 39072750 — intervention group
Group type: COMPARATOR
Intervention: TILs in metastases
Number of subjects: 550
Study 39072750 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression
Number of subjects: 550
Study 39073058 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Body Weight Support (PBWS) harness system
Number of subjects: 17
Study 39073058 — intervention group
Group type: COMPARATOR
Intervention: Play without the harness engaged
Number of subjects: 17
Study 39073142 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and Ribociclib
Number of subjects: 0
Study 39073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Axis-flip cases (FC)
Number of subjects: 84
Study 39073343 — intervention group
Group type: COMPARATOR
Intervention: Unflipped cases (UF)
Number of subjects: 84
Study 39073370 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 20
Study 39073370 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 39073518 — intervention group
Group type: COMPARATOR
Intervention: Group Intervention - Collective Advocacy - Individual Counseling (GI-CA-IC) sequence
Number of subjects: 940
Study 39073518 — intervention group
Group type: COMPARATOR
Intervention: Intervention package conducted simultaneously at pilot site
Number of subjects: 940
Study 39073518 — intervention group
Group type: COMPARATOR
Intervention: Collective Advocacy - Individual Counseling - Group Intervention (CA-IC-GI) sequence
Number of subjects: 940
Study 39073523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 555
Study 39073523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 39073574 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab + methotrexate
Number of subjects: 30
Study 39073574 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab + csDMARDs
Number of subjects: 30
Study 39073574 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab monotherapy
Number of subjects: 30
Study 39073574 — intervention group
Group type: COMPARATOR
Intervention: Control (csDMARDs)
Number of subjects: 30
Study 39073574 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 39073574 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI scores
Number of subjects: 30
Study 39073577 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR monotherapy
Number of subjects: 91
Study 39073577 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR + csDMARDs
Number of subjects: 91